Personalis, Inc. 10-K

Item 9A. Controls and Procedures. Evaluation of Disclosure Controls and Procedures Our management, with the participation of our chief executive officer ("CEO") and chief financial officer ("CFO") has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or Exchange Act), as of the end of the period covered by this Annual Report on Form 10-K. Based on that evaluation, our CEO and CFO have concluded that as of December 31, 2025, our disclosure controls and procedures were effective in providing reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosures. Management Report on Internal Control over Financial Reporting Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) of the 1934 Act. Management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2025 based on criteria established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. As a result of this assessment, management concluded that, as of December 31, 2025, our internal control over financial reporting was effective in providing reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America. Our independent registered accounting firm is not required to issue an attestation report on our internal control over financial reporting for so long as we qualify as a non-accelerated filer. Changes in Internal Control Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Rule 13a-15(f) of the Exchange Act. An evaluation was also performed under the supervision and with the participation of our management, including our CEO and our CFO, of any change in our internal control over financial reporting that occurred during our last fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any change in our internal control over financial reporting that occurred during our latest fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Limitations on Controls Our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives as specified above. Management does not expect, however, that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected. 99 Table of Contents Item 9B. Other Information. Trading Arrangements During the last fiscal quarter, certain of our officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted written plans for the sale of our securities as set forth in the table below. Type of Trading Arrangement Name and Position Action Adoption Date Rule 10b5-1* Non-Rule 10b5-1** Total Shares of Common Stock to be Sold Expiration Date Christopher Hall , President & CEO Adoption December 17, 2025 X 400,000 December 31, 2026 Richard Chen , EVP, R&D, Chief Medical Officer Adoption December 23, 2025 X 900,000 March 22, 2027 * Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. **Non-Rule 10b5-1 trading arrangement as defined in Item 408(c) of Regulation S-K under the Exchange Act. Amended and Restated Bylaws On February 24, 2026, our board of directors amended and restated the Company’s Amended and Restated Bylaws (the “Amended Bylaws”), effective immediately. Among other changes, the Amended Bylaws: • Modernize the stockholder proposal procedures and disclosure requirements set forth in Section 5 of the Amended Bylaws, including, without limitation, by adding certain requirements for stockholder nominated directors to furnish information supporting their eligibility to serve, limiting the number of nominees a stockholder may nominate for election, limiting the need to provide information about the other stockholders supporting the proposal to those who are financially supporting such proposal, adding additional disclosure requirements to disclose in a director nomination proposal notice relating to certain extrinsic arrangements and requiring stockholder (or a qualified representative of the stockholder) appearance at the annual or special meeting of stockholders of the Company to present a nomination or proposed business advanced by such stockholder; • Clarify that certain updates to a previously submitted stockholder proposal, including, without limitation, change or addition of nominees, matters, business and/or resolutions to be brought before the meeting, will not be permitted as updates and will instead constitute a new proposal and be subject to the stockholder proposal procedures and disclosure requirements set forth in Section 5 of the Amended Bylaws; • Simplify the description of the voting standards for the election of directors and other proposals at stockholder meetings in Section 8 of the Amended Bylaws; • Conform the notice provisions throughout the Amended Bylaws to the requirements of Section 232 of the General Corporation Law of the State of Delaware (the “DGCL”); and • Conform Section 12 of the Amended Bylaws concerning the list of stockholders in connection with stockholder meetings with the requirements of Section 219 of the DGCL. The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amended Bylaws, which are filed as Exhibit 3.2 to this Annual Report on Form 10-K. Item 9C. Discl osure Regarding Foreign Jurisdictions that Prevent Inspections. Not applicable. 100 Table of Contents PART III Item 10. Directors, Executive Off icers and Corporate Governance. Except for the principal occupation, business experience, and education of each of our executive officers and directors set forth further below, the information required by this Item is set forth under the headings “Executive Officers,” “Security Ownership of Certain Beneficial Owners and Management,” “Corporate Governance and Board of Directors Matters,” and “Proposal No. 1 Election of Directors—Information About Our Continuing Directors” in the Company’s 2026 Proxy Statement to be filed with the SEC within 120 days after December 31, 2025 in connection with the solicitation of proxies for the Company’s 2026 annual meeting of stockholders, and is incorporated herein by reference. Our board of directors has adopted a Code of Business Conduct and Ethics applicable to all officers, directors and employees, which is available on our website (investors.personalis.com) under "Corporate Governance." We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding amendment to, or waiver from, a provision of our Code of Business Conduct and Ethics by posting such information on the website address and location specified above. The principal occupation, business experience, and education of each of our executive officers and directors are set forth below. Executive Officers Christopher Hall. Mr. Hall has served as our Chief Executive Officer and President since March 2023 and before that served as our Senior Vice President and Head, Diagnostics Business upon joining our company in October 2022. Mr. Hall has also served as a member of the Board of Directors since March 2023. From October 2020 to July 2022, Mr. Hall served as Chief Executive Officer of Naring Health, Inc., a medical research services company. From February 2010 to July 2019, Mr. Hall served as President, Chief Operating Officer, and Chief Commercial Officer at Veracyte, Inc., a publicly traded global diagnostics company. Mr. Hall holds a B.A. in Political Science and Economics from DePauw University and an M.B.A. from Harvard Business School. Aaron Tachibana. Mr. Tachibana has served as our Chief Financial Officer since March 2019 and has also served as our Chief Operating Officer since March 2023. From December 2022 to March 2023, Mr. Tachibana served as our interim Chief Executive Officer. From August 2015 to September 2018, Mr. Tachibana served as Chief Financial Officer at Lumentum Holdings Inc., a designer and manufacturer of optical and photonic products. From November 2013 to July 2015, Mr. Tachibana served as Vice President, Finance and Corporate Controller at JDS Uniphase Corp., subsequently renamed Viavi Solutions Inc., a network test, measurement, and assurance technology company. From March 2010 to October 2013, Mr. Tachibana served as Chief Financial Officer at Pericom Semiconductor Corp., a supplier of high-performance connectivity and timing solutions. Mr. Tachibana holds a B.S. in Business Administration and Finance from San Jose State University. Richard Chen, M.D., M.S. Dr. Chen has served as our Chief Medical Officer since November 2011 (previously designated Chief Scientific Officer). In March 2023, Dr. Chen was promoted to Executive Vice President, R&D, in addition to his role as Chief Medical Officer. Since September 2011, Dr. Chen has served on the clinical faculty at Stanford University School of Medicine. In August 1997, Dr. Chen co-founded Ingenuity Systems, a genomic data software company. Dr. Chen holds a B.S. in Computer Science from Stanford University, an M.S. in Medical Informatics from Stanford University School of Medicine, and an M.D. from Stanford University School of Medicine. Stephen Moore. Mr. Moore has served as our Vice President and General Counsel since April 2020 and as Corporate Secretary since May 2020. In February 2024, Mr. Moore was promoted to Senior Vice President and Chief Legal Officer. From October 2014 to April 2020, Mr. Moore served as General Counsel and Corporate Secretary at Pacific Biosciences of California, Inc., a publicly traded advanced genomics company. From January 2010 to October 2014, Mr. Moore served in other roles at Pacific Biosciences of California, Inc., including Associate General Counsel and Senior Director of Commercial Legal Affairs, and Vice President, Legal Affairs. From June 2007 to December 2009, Mr. Moore served as General Counsel and Corporate Secretary at Navigenics, Inc., a consumer genomics company. From January 1999 to June 2007, Mr. Moore held various positions at Affymetrix, Inc., a microarray company, including Associate General Counsel. Mr. Moore holds a B.A. in Political Science from San Jose State University and a J.D. from University of California, Davis. Independent Directors Olivia K. Bloom. Ms. Bloom has served on our Board of Directors since March 2022. In September 2023, after a 29-year career with Geron Corporation, a publicly traded commercial-stage biopharmaceutical company, Ms. Bloom retired as Executive Vice President, Chief Financial Officer and Treasurer. During that tenure, Ms. Bloom held several financial management positions, including Chief Accounting Officer and Controller, as well as lead several operational functions, including purchasing, information technology and investor relations. Ms. Bloom started her career in public accounting at KPMG International Limited and became a Certified Public Accountant in 1994. Ms. Bloom holds a B.S. in Business Administration from the University of California, Berkeley. Ms. Bloom was selected to serve on our Board of Directors because of her expertise in finance, accounting, and corporate governance and her experience as a senior female executive working for and with publicly-traded life science companies. 101 Table of Contents A. Blaine Bowman. Mr. Bowman has served on our Board of Directors since May 2019. Beginning in 2006, Mr. Bowman served on the board of directors of Solexa, Inc., a DNA sequencing company, until its sale to Illumina, Inc., a publicly traded biotechnology company and leader in DNA sequencing in January 2007, after which Mr. Bowman continued to serve on the board of directors of Illumina, Inc. until May 2018. From March 1977 to August 2005, Mr. Bowman served in various roles at Dionex Corporation, a publicly traded manufacturer of analytical instruments, including Chairman of the board of directors, President, and Chief Executive Officer, and he served on the board of directors until its sale to Thermo Fisher Scientific Inc. in May 2011. From July 2012 to December 2015, Mr. Bowman served on the board of directors of Altera Corporation, a publicly traded programmable logic devices company. Mr. Bowman holds a B.S. in Physics from Brigham Young University and an M.B.A. from the Stanford Graduate School of Business. Mr. Bowman was selected to serve on our Board of Directors because of his experience in executive roles and his experience serving on the boards of directors of various instrumentation and biotechnology companies. Karin Eastham. Ms. Eastham has served on our Board of Directors since September 2019. Ms. Eastham has served on the board of Veracyte, Inc., a publicly traded genomic diagnostics company, since December 2012. Ms. Eastham previously served as a member of the board of directors of Nektar Therapeutics, Inc., a publicly traded biopharmaceutical company, from September 2018 to June 2023; Geron Corporation, a publicly traded clinical stage biopharmaceutical company, from March 2009 to May 2023; and Illumina, Inc., a publicly traded biotechnology company and leader in DNA sequencing, from August 2004 to May 2019. From May 2004 to September 2008, Ms. Eastham served as Executive Vice President and Chief Operating Officer, and as a member of the Board of Trustees, of the Burnham Institute for Medical Research, a non-profit corporation engaged in biomedical research. Ms. Eastham holds a B.S. in Accounting and an M.B.A. from Indiana University and is a Certified Public Accountant (inactive). Ms. Eastham was selected to serve on our Board of Directors because of her expertise in financial and operations management and experience serving on the boards of publicly-traded life science companies. Woodrow A. Myers, Jr., M.D. Dr. Myers has served on our Board of Directors since March 2021. Dr. Myers serves as an Advisor to Lightspeed Venture Partners Inc., to the SCAN Group and to eHealth Inc. From May 2007 to December 2018, Dr. Myers served on the board of directors of Express Scripts Inc., a publicly traded health care company. From January 2018 to February 2019, Dr. Myers served as Chief Medical Officer and Chief Healthcare Strategist for Blue Cross Blue Shield of Arizona. He has also served as the Chief Medical Officer of Wellpoint Health Networks and Director of Healthcare Management for the Ford Motor Company. In the public sector he has served as the Health Commissioner of New York City and the State of Indiana. Since December 2015, Dr. Myers has served as Managing Director of Myers Ventures LLC, a healthcare consulting company. Dr. Myers holds a B.S. in Biology from Stanford University, an M.B.A. from Stanford Graduate School of Business, and an M.D. from Harvard Medical School. Dr. Myers was selected to serve on our Board of Directors because of his extensive experience in the healthcare industry, including in government and health policy roles. Lonnie Shoff. Ms. Shoff has served on our Board of Directors since August 2022. Ms. Shoff has served as President of Antech and Sound Diagnostics, a business unit of Mars Petcare, since April 2020. From September 2016 to April 2020, Ms. Shoff served as President of the Clinical Diagnostics Division at Thermo Fisher Scientific Inc. From September 2009 to May 2016, Ms. Shoff held various positions at Henry Schein, a publicly traded health care product distributor, including Chief Executive Officer of the Global Animal Health and Strategic Partnership Group and President of the Global Healthcare Specialty Group. Ms. Shoff also held positions of increasing responsibility including the Senior Vice President & General Manager of Molecular Diagnostic and Applied Science at Roche, a Swiss multinational healthcare company, from August 1988 to September 2009. Ms. Shoff holds a B.S. in Biology from Purdue University. Kenneth J. Widder, M.D. Mr. Widder has served on our Board of Directors since June 2023. Dr. Widder currently serves on the boards of QuidelOrtho Corporation and Evoke Pharma, Inc. and has over 40 years of experience working with biomedical companies, having previously served as a founder, director and/or CEO of Sydnexis, Inc., OrphoMed, Inc., Sytera, Inc., NovaCardia, Inc., Santarus, Inc., and Molecular Biosystems Inc., and as a general partner at LVP Life Science Ventures (formerly Latterell Venture Partners) and Windamere Venture Partners. He holds an MD from Northwestern University and trained in pathology at Duke University. Item 11. Executiv e Compensation. The information required by this Item is set forth under the headings “Director Compensation,” and “Executive Compensation” in the Company’s 2026 Proxy Statement to be filed with the SEC within 120 days after December 31, 2025, and is incorporated herein by reference. Item 12. Security Ownership of Certain Beneficial Own ers and Management and Related Stockholder Matters. The information required by this Item is set forth under the headings “Equity Compensation Plans at December 31, 2025” and “Security Ownership of Certain Beneficial Owners and Management” in the Company’s 2026 Proxy Statement to be filed with the SEC within 120 days after December 31, 2025, and is incorporated herein by reference. Item 13. Certain Relationships and Related Transactions, and Director Independence. The information required by this Item is set forth under the headings “Corporate Governance and Board of Directors Matters” and “Transactions with Related Persons and Indemnification” in the Company’s 2026 Proxy Statement to be filed with the SEC within 120 days after December 31, 2025, and is incorporated herein by reference. 102 Table of Contents Item 14. Principal Accoun tant Fees and Services. The information required by this Item is set forth under the headings “Principal Accountant Fees and Services” and “Pre-Approval Procedures” under the proposal “Ratification of Selection of Independent Registered Public Accounting Firm” in the Company’s 2026 Proxy Statement to be filed with the SEC within 120 days after December 31, 2025, and is incorporated herein by reference. 103 Table of Contents PART IV Item 15. Exhibits, Financi al Statement Schedules. (a) Financial Statements and Schedules The financial statements are set forth under Item 8 of this Annual Report on Form 10-K, as indexed below. Financial statement schedules have been omitted since they either are not required, not applicable, or the information is otherwise included. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Consolidated Balance Sheets 70 Consolidated Statements of Operations 71 Consolidated Statements of Comprehensive Loss 72 Consolidated Statements of Stockholders’ Equity 73 Consolidated Statements of Cash Flows 74 Notes to Consolidated Financial Statements 75 Report of Independent Registered Public Accounting Firm 97 (b) Exhibits Incorporated by Reference Exhibit Number Description Form File No. Exhibit Filing Date 3.1 Amended and Restated Certificate of Incorporation of the Registrant. 8-K 001-38943 3.1 6/24/2019 3.2* Amended and Restated Bylaws of the Registrant. 4.1 Description of Securities of Personalis, Inc. 10-K 001-38943 4.1 2/25/2021 4.2 Form of Common Stock Certificate of the Registrant. S-1/A 333-231703 4.1 6/7/2019 4.3 Investment Agreement, dated August 16, 2024, by and between the Registrant and Tempus AI, Inc. 8-K 001-38943 4.1 8/16/2024 4.4 Investment Agreement, dated December 19, 2024, by and between the Registrant and Merck Sharp & Dohme LLC. 8-K 001-38943 4.1 12/19/2024 10.1# Personalis, Inc. 2011 Equity Incentive Plan, as amended, and forms of agreements thereunder. S-1 333-231703 10.1 5/23/2019 10.2# Personalis, Inc. 2019 Equity Incentive Plan and forms of agreements thereunder. S-1/A 333-231703 10.2 6/7/2019 10.3# Personalis, Inc. 2019 Employee Stock Purchase Plan. S-1/A 333-231703 10.3 6/7/2019 10.4*# Personalis, Inc. 2020 Inducement Plan, as amended. 10.5# Form of RSU Award Agreement under 2020 Inducement Plan. 10-K 001-38943 10.5 2/28/2024 10.6# Form of Option Agreement under 2020 Inducement Plan. 10-K 001-38943 10.6 2/28/2024 10.7# Form of Indemnification Agreement entered into by and between the Registrant and each director and executive officer. S-1/A 333-231703 10.4 6/7/2019 10.8# Amended and Restated Non-Employee Director Compensation Policy, dated February 27, 2024 10-Q 001-38943 10.1 5/8/2024 10.9# Amended and Restated Employment Agreement dated March 7, 2023, between the Registrant and Aaron Tachibana. 8-K 001-38943 10.1 3/8/2023 10.10# Amended and Restated Offer Letter, dated March 7, 2023, between the Registrant and Christopher Hall. 8-K 001-38943 10.2 3/8/2023 10.11# Amended and Restated Employment Agreement dated March 8, 2023, between the Registrant and Richard Chen. 8-K 001-38943 10.3 3/8/2023 10.12# Second Amended and Restated Executive Severance Agreement, dated September 25, 2023, between the Registrant and Christopher Hall. 10-K 001-38943 10.12 2/28/2024 10.13# Third Amended and Restated Executive Severance Agreement, dated September 25, 2023, between the Registrant and Aaron Tachibana. 10-K 001-38943 10.13 2/28/2024 10.14# Third Amended and Restated Executive Severance Agreement, dated September 25, 2023, between the Registrant and Richard Chen. 10-K 001-38943 10.14 2/28/2024 10.15# Second Amended and Restated Executive Severance Agreement, dated September 18, 2023, between the Registrant and Stephen Moore. 10-K 001-38943 10.15 2/28/2024 10.16Ω‡ Commercialization and Reference Laboratory Agreement, between the Registrant and Tempus AI, Inc., dated November 25, 2023. 8-K 001-38943 10.1 11/28/2023 104 Table of Contents 10.17Ω‡ Amendment No. 1 to the Commercialization and Reference Laboratory Agreement, dated August 16, 2024, by and between the Registrant and Tempus AI, Inc. 8-K 001-38943 10.1 8/16/2024 10.18 Amendment No. 2 to the Commercialization and Reference Laboratory Agreement, dated September 20, 2024, by and between the Registrant and Tempus AI, Inc . 10-Q 001-38943 10.2 11/6/2024 10.19Ω Amendment No. 3 to the Commercialization and Reference Laboratory Agreement, dated December 13, 2024, by and between the Registrant and Tempus AI, Inc. 10-K 001-38943 10.19 2/27/2025 10.20 Lease, by and between MENLO PREHC I, LLC, MENLO PREPI I, LLC, TPI INVESTORS 9, LLC and the Registrant, dated February 2, 2015. S-1 333-231703 10.9 5/23/2019 10.21 First Amendment to Lease, by and between MENLO PREPI I, LLC and TPI INVESTORS 9, LLC and the Registrant, dated April 8, 2020. 10-Q 001-38943 10.1 8/6/2020 10.22 Lease, by and between Ardenwood Ventures I, LLC and the Registrant, dated August 25, 2021. 10-Q 001-38943 10.1 11/4/2021 10.23 Amendment No. 1 to Lease, by and between Ardenwood Ventures I, LLC and the Registrant, dated December 8, 2021. 10-K 001-38943 10.16 2/24/2022 10.24 Amendment No. 2 to Lease, by and between Ardenwood Ventures I, LLC and the Registrant, dated June 9, 2022. 10-Q 001-38943 10.1 8/3/2022 10.25 Amendment No. 3 to Lease, by and between Ardenwood Ventures I, LLC and the Registrant, dated December 19, 2022. 10-K 001-38943 10.19 2/23/2023 10.26‡ Contract No. 36C24E22D0031, by and between the U.S. Department of Veterans Affairs and the Registrant, dated September 30, 2022. 10-Q 001-38943 10.1 11/2/2022 10.27Ω Amendment No. 4 to the Commercialization and Reference Laboratory Agreement, dated July 8, 2025, by and between the Registrant and Tempus AI, Inc. 10-Q 001-38943 10.1 11/4/2025 10.28 Amendment No. 5 to the Commercialization and Reference Laboratory Agreement, dated September 11, 2025, by and between the Registrant and Tempus AI, Inc. 10-Q 001-38943 10.2 11/4/2025 10.29 Amended and Restated At-the-Market Sales Agreement, dated December 27, 2024, by and among the Registrant, Piper Sandler & Co. and BTIG, LLC. 8-K 001-38943 1.1 12/27/2024 10.30Ω‡ Settlement and License Agreement, between the Registrant. and Foresight Diagnostics, Inc., dated June 21, 2024. 10-Q 001-38943 10.1 8/7/2024 19.1* Insider Trading Policy. 21.1* Subsidiaries of the Registrant as of December 31, 2025. 23.1* Consent of Independent Registered Public Accounting Firm. 24.1* Power of Attorney (included on the Signatures page of this Annual Report on Form 10-K). 31.1* Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2* Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1*† Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 32.2*† Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 97# Incentive Compensation Recoupment Policy. 10-K 001-38943 97 2/28/2024 101* Inline XBRL Document Set for the consolidated financial statements and accompanying notes in Part II, Item 8, “Financial Statements and Supplementary Data” of this Annual Report on Form 10-K. 104* Inline XBRL for the cover page of this Annual Report on Form 10-K, included in the Exhibit 101 Inline XBRL Document Set. # Indicates management contract or compensatory plan or arrangement. * Filed herewith. 105 Table of Contents † The certifications attached as Exhibit 32.1 and Exhibit 32.2 that accompany this Annual Report on Form 10-K are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing. Ω Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the SEC, certain portions of this exhibit have been redacted because the Company customarily and actually treats such omitted information as private or confidential and because such omitted information is not material. ‡ Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K because such schedules and exhibits do not contain information which is material to an investment or voting decision or which is not otherwise disclosed in the filed agreements. The Company will furnish the omitted schedules and exhibits to the SEC upon request by the SEC. Item 16. Form 10-K Summary None. 106 Table of Contents SIGNAT URES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized . Date: February 26, 2026 Personalis, Inc. By: /s/ Aaron Tachibana Aaron Tachibana Chief Financial Officer and Chief Operating Officer (Principal Financial and Accounting Officer) POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Christopher Hall and Aaron Tachibana, jointly and severally, his or her attorneys-in-fact, each with the power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated: Name and Signature Title Date /s/ Christopher Hall President, Chief Executive Officer and Director February 26, 2026 Christopher Hall (Principal Executive Officer) /s/ Aaron Tachibana Chief Financial Officer and Chief Operating Officer February 26, 2026 Aaron Tachibana (Principal Financial and Accounting Officer) /s/ Karin Eastham Director February 26, 2026 Karin Eastham /s/ Olivia Bloom Director February 26, 2026 Olivia K. Bloom /s/ A. Blaine Bowman Director February 26, 2026 A. Blaine Bowman /s/ Woodrow A. Myers, Jr. Director February 26, 2026 Woodrow A. Myers, Jr., M.D. /s/ Lonnie Shoff Director February 26, 2026 Lonnie Shoff /s/ Kenneth Widder Director February 26, 2026 Kenneth J. Widder, M.D. 107